Literature DB >> 19934590

Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy.

Hideyuki Harada1, Hirohisa Katagiri, Minoru Kamata, Yasuo Yoshioka, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Mitsuru Takahashi, Harumi Sakahara, Tetsuo Nishimura.   

Abstract

We evaluated the radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. 102 consecutive patients with femoral metastases without pathological fracture were treated by surgery or radiotherapy between 2002 and 2005. Twelve of them initially treated with surgery were excluded from this study. The remaining 90 patients with 102 lesions underwent radiation therapy as the initial treatment. Twelve patients who died within 30 days by disease progression and 6 who were lost to follow-up were excluded. The remaining 72 patients with 84 lesions including 43 impending fractures were enrolled in this analysis. Radiological changes were categorized into complete response, partial response, no change, and progressive disease based on plain radiograph findings. Pain relief was reviewed for 77 painful lesions. The median radiation dose was 30 Gy. No re-irradiation was performed. 35 lesions (42%) achieved radiological responses median 3 months after radiotherapy. Pain relief was obtained in 36 of 77 lesions (47%). There was no significant correlation between radiological response and pain relief (P = 0.166). Eleven lesions eventually required surgery and considered as treatment failure. The treatment failure rate in the radiological progressive disease (PD) group (8/19, 42%) was significantly higher than that in the non-PD group (3/65, 5%) (P < 0.001). Among 43 impending fracture lesions, 15 lesions (36%) experienced radiological response and 35 lesions (81%) required no surgical interventions. Our data suggest that radiotherapy can enable metastatic bone healing and avoid surgery in many lesions. However, radiological PD lesions often require surgery after radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934590     DOI: 10.1269/jrr.09096

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  12 in total

1.  Langerhans' cell histiocytosis in the pediatric spine: therapeutic dynamic change of spinal deformity.

Authors:  Yi-Chieh Hung; Feng-Chi Chang; Yi-Wei Chen; Mul-Li Liang; Hsin-Hung Chen; Sanford P C Hsu; Huai-Che Yang; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2012-04-29       Impact factor: 1.475

2.  Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.

Authors:  Seiichi Hosaka; Hirohisa Katagiri; Masashi Niwakawa; Hideyuki Harada; Junji Wasa; Hideki Murata; Mitsuru Takahashi
Journal:  Int J Clin Oncol       Date:  2018-06-29       Impact factor: 3.402

Review 3.  Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine?

Authors:  Alysa Fairchild
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Skeletal Related Events are Rare After Radiation Treatment for Metastatic Disease of the Femur.

Authors:  Zachary Mayo; Bryan G Allen; Qiang An; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2021

5.  The burden of metastatic disease of the femur on the Medicare system.

Authors:  Kirollos Gendi; David Hennessy; John Heiner
Journal:  Springerplus       Date:  2016-11-04

6.  Limited short-term effect of palliative radiation therapy on quantitative computed tomography-derived bone mineral density in femora with metastases.

Authors:  Florieke Eggermont; Loes C Derikx; Nico Verdonschot; Gerjon Hannink; Robert S J P Kaatee; Esther Tanck; Yvette M van der Linden
Journal:  Adv Radiat Oncol       Date:  2016-11-10

7.  Fracture after radiation therapy for femoral metastasis: incidence, timing and clinical features.

Authors:  Tetsuo Shimoyama; Hirohisa Katagiri; Hideyuki Harada; Hideki Murata; Junji Wasa; Seiichi Hosaka; Takayoshi Suzuki; Mitsuru Takahashi; Hirofumi Asakura; Tetsuo Nishimura; Harumoto Yamada
Journal:  J Radiat Res       Date:  2017-09-01       Impact factor: 2.724

8.  Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.

Authors:  Milda Rudzianskiene; Arturas Inciura; Rolandas Gerbutavicius; Viktoras Rudzianskas; Andrius Macas; Renata Simoliuniene; Ruta Dambrauskiene; Greta Emilia Kiavialaitis; Elona Juozaityte
Journal:  Strahlenther Onkol       Date:  2017-06-01       Impact factor: 3.621

9.  The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases.

Authors:  Tanja Sprave; Katharina Hees; Thomas Bruckner; Robert Foerster; Tilman Bostel; Ingmar Schlampp; Rami El Shafie; Nils Henrik Nicolay; Juergen Debus; Harald Rief
Journal:  Radiat Oncol       Date:  2018-07-24       Impact factor: 3.481

10.  The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era.

Authors:  Lucas Resende Salgado; Shutao Wang; Ava Adler; Sanders Chang; Meng Ru; Erin Moshier; Kavita Dharmarajan; Hearn Jay Cho; Richard Bakst
Journal:  Adv Radiat Oncol       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.